Skip to Main Content

A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Conditions

Phase I

Phase I

What is the purpose of this trial?

The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.

  • Trial with
    I-Mab Biopharma, Co., Ltd
  • Start Date
    10/12/2020
  • End Date
    02/21/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000025819